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 ABSTRACT                                                                                                                                            
Association of the UCP2 –866G/A polymorphism with 
type 2 diabetes and obesity in Saudi population
Mohammed T. Tayeb
Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura 
University, Makkah, KSA.
Background: Diabetes mellitus is emerging as a major public health problem 
allover the world particularly Saudi Arabia. Recent studies reported that Un-
coupling Protein 2 (UCP2) was associated with obesity and type 2 diabetes 
(T2D).
Aim of the Study: This study was conducted to clarify the contribution of 
polymorphism in UCP2 in obesity and T2D in the Saudi population. 
Subjects and Methods: The distribution of the –866G/A polymorphism was 
examined in a case-control study including samples from 110 obese patients, 
81 T2D patients, 96 obese-T2D patients and 100 healthy unrelated Saudi sub-
jects. The –866G/A polymorphism were determined by using PCR/RFLP (poly-
merase chain reaction/restriction fragment length polymorphism) techniques. 
Results: The results of this study showed that the frequency of the GG geno-
type was significantly higher in both obese and T2D patients (p-value= 0.0001, 
p-value= 0.014, respectively) compared with healthy control. The G allele was 
significantly associated with increase risk of obesity (odd ratio, OR: 3.3; 95% 
confidence interval, CI: 1.37-7.98), but not with T2D (OR, 1.97; Cl, 0.80-4.87). 
In obese-T2D patients group, no significant correlation with –866G/A poly-
morphism (p= 0.067; OR, 1.21; Cl, 0.25-2.80). This unreeled study suggest-
ed that the G allele of UCP2 –866G/A polymorphism was related to obesity, 
which indicated the possible role of this polymorphism in causing metabolic 
syndrome. 
Conclusion: This study concluded that the G allele of UCP2 –866G/A poly-
morphism might be related to obesity and T2D which might be used as a pre-
dictive marker for obesity and T2D.




T2D, Obesity, Uncoupling protein 2 
(UCP2) gene, –866G/A polymorphism, 
Saudi population.
INTRODUCTION                                        
Type 2 diabetes (T2D) is one of the 
most common is a health-care problem 
worldwide affecting both industrial and 
developing nations. A clear link has 
been made between genetic defects and 
the less common monogenic forms of 
diabetes, such as maturity onset diabetes 
of the young (MODY) and neonatal 
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diabetes1,2. Conversely, the genetics 
underlying T2D is multifactorial and 
complex in nature3 with several genes 
simultaneously involved.4 
Uncoupling protein 2 (UCP2) 
belongs to the superfamily of the 
mitochondrial transporter proteins and 
is highly expressed in adipose tissue and 
pancreatic islets5. Although UCP2 does 
not contribute substantially to adaptive 
thermogenesis in humans, it may play 
an important role in the regulation of 
fuel metabolism by direct and indirect 
actions in the adipose tissue, skeletal 
muscle and the endocrine pancreas6. 
Moreover, UCP2 inhibits lipogenesis in 
the adipose tissue7 and insulin secretion 
in pancreatic islets.8 
In the Goto-Kazizaki rat, the UCP2 
gene is linked to D1Wox38 marker (at 
87.9 cM of the rat chromosome 1)9, 
which is located in a region where a 
relevant number of linkage peaks for 
glucose intolerance and adiposity have 
been identified. 
In humans, the 11q13 chromosomal 
region (which contains the UCP2 gene) 
is weakly linked to T2D in Finns10, but 
not in other populations11. In Finns, by 
a genome scan performed at an average 
resolution of 8 cM, the most relevant 
logarithm of the odds (LOD) score 
peak in 11q13, lies about 8 cM from 
the UCP2 gene locus10. Taken together, 
it is apparent that the UCP2 gene is an 
excellent candidate for T2D. 
Several UCP2 gene variants have 
been reported in human studies: 
A G/A mutation in the promoter 
region –866G/A12,13, a valine-alanine 
substitution at amino acid 55 in exon-
4 (Ala55Val)14,15 and a 45-base-pair 
insertion and deletion in the untranslated 
region of exon-816,17. The association 
between these polymorphisms in UCP2 
and various aspects of obesity has been 
studied intensively. A functional –866G/
A single nucleotide polymorphism 
(SNP) has been described in the 
UCP2 promoter12. The –866A allele 
has been reported to increase UCP2 
transcriptional activity in transfected 
cultured cells13. However data in human 
tissues have been conflicting, reporting 
either increased13, or decreased18 UCP2 
mRNA levels in association with the 
–866A allele. 
The present study aimed to evaluate the 
association of the common –866G/A 
SNP of the UCP2 gene in T2D subjects 
with and without obesity of Saudi 
origin.
SUBJECTS AND METHODS                      
Study Population:
Both cases and controls were of Saudi 
origin and resident in the Western re-
gions. For the sake of accuracy, this 
study focused only on those subjects 
for whom specific clinical information 
was available. Cases were 387 selected 
from 491 patients. Permission to per-
form this study was obtained from the 
ethical committee of the Faculty of 
Medicine, Umm Al-Qura University-
Makkah. Informed consents from the 
cases to obtain the data used in this 
study were taken. The present study 
comprised three groups of unrelated pa-
tients: 81 T2D, 110 obese and 96 T2D-
obese. Patients with T2D were consecu-
tively recruited who met the following 
criteria: 1) diabetes diagnosed after 25 
years, 2) insulin treatment not required 
for at least 2 years after diabetes di-
agnosed and 3) absence of clinically 
evident autoimmune disease. Obese 
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subjects considered if their body mass 
indexes (BMI) ≥30 kg/m2 (according 
to American Obesity Association 2005; 
(http://www.obesity.org). In addition, 
age-matched healthy volunteers con-
sist of 100 subjects were randomly 
selected. 
Selection criteria of control group were 
as follows: fasting plasma glucose < 6.1 
mmol/L, no medications known to af-
fect glucose and lipid metabolism, and 
absence of systemic diseases. They did 
not have a family history for T2D or 
obesity at first degree relative. Patients, 
who were under certain medication (e.g. 
cortisone) which could be the reason for 
their obesity, or could lead them to dia-
betes, were excluded from the study at 
time of sampling. In addition, patients 
who had endocrinal disorders that af-
fected their weights (e.g. Cushing dis-
ease, hypothyroidism) and the female 
volunteers who had polycyctic ovarian 
syndrome (PCOS) were also excluded. 
The clinical features of T2D, obese and 
T2D-obese, besides the healthy con-
trol group of the Saudi subjects ± stan-
dard deviations (SD) were showed in 
Table 1.
Table 1: Characteristics of phenotypic parameters: Means of age and body mass index 
(BMI) ± SD.
Parameter Age range (y) (mean+SD) BMI range (mean+SD)(kg/m2) Female/Male
T2D 27–67 (51.1±10.0) 18–30 (25.3±2.6) 30/51
Obesity 20–67 (32.3±10.0) 30–65 (36.2±5.6) 29/81
Obesity-T2D 20–74 (49.7±10.5) 30–59 (35.1±4.7) 48/48
Healthy Controls 20–80 (35.3±9.0) 18–25 (23.0±1.9) 27/73
DNA Extraction:
Genomic DNA was extracted from 
blood lymphocytes using SpinColumn 
genomic DNA kit (BioBasic Inc., On-
tario, Canada).
PCR Assay:
Previously described primer sets12 
were used to amplify regions around 
the UCP2 –866G/A promoter re-
gion (forward primer, 5`-CACGCT-
GCTTCTGCCAGGAC-3` and reverse 
primer, 5`-AGGCGTCAGGAGATG-
GACCG-3`. Genomic DNA (200 ng) 
was added to a 15- μl reaction mix-
ture containing 0.5 μM of each primer 
with 200 μM of each dNTP’s, 67 mM 
Tris-HCl, 16 mM (NH4)2SO4, 0.01% 
Tween-20, 1mM MgCl2, and 0.45 U Taq 
DNA polymerase. Amplification condi-
tions were 95°C for 5 min followed by 
30 rounds of 95° for 30s, 68° for 30s, 
72° for 45s. A final extension of 72° for 
5 min was included.
Genotype Analysis: 
Following amplification, PCR ampli-
con (5 μl) was incubated with 5 U of 
MluI (New England Biolabs) at 37°C 
for 2 h. The digested PCR fragments 
were separated on 3% MetaPhor gel 
(BMA Bioproducts Inc., USA), visual-
ized by ethidium bromide staining and 
recorded by Gel Documentation and 
Analysis System (UVitec, Cambridge, 
UK). The – 866GG genotype was 
cleaved into two fragments (290- & 
70-bp), whereas the AA genotype lack 
the recognition site and gave rise to a 
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fragment at 360 bp (Fig. 1). Automated 
sequencing was used (ABI PRISM 310 
Genetic Analyser (Perkin Elmer-ABI, 
Warrington, UK)) to confirm validation 
of digest assay and to select positive 
control samples. Homozygous uncut 
(AA), heterozygous (GA) and homozy-
gous cut (GG) were determined.
Fig. 1: Gel patterns of UCP2 –866G/A 
polymorphism. The Mlu I restriction enzyme 
differentiated the UCP2 –866G/A polymorphism. 
Lane 1, represents the GG genotype due to the 
complete cutting the PCR fragment (360 bp) into 
2 fragments (290 and 70 bp). The AA genotype 
in lane 3 shows the uncut PCR fragment (360-
bp), while the heterozygote GA genotype was 
in lane 2. MW is a 50 bp ladder (lane 4) was 
separated on 3% agarose gel.
Statistical Analysis:
The frequency distribution of allele 
and genotypes in the studied popula-
tion were compared statistically using 
the Chi-squared test (Minitab version 
12.1, Minitab Inc., Coventry, UK). Har-
dy-Weinberg analysis was done using 
CLUMP software version 1.2. The odd 
ratio (OR) for UCP2 marker was calcu-
lated by using STATA 1.0 software. T-
test (Minitab version 12.1, Minitab Inc., 
Coventry, UK) was used to determine 
if there is a difference between groups 
regarding the age and BMI.
RESULTS                                                                                                        
The inherited genotypes –866G>A in 
the promoter region of the UCP2 gene 
were determined. Genotype and allele 
frequencies of UCP2 gene in Saudi 
subjects were shown in (Tables 2 and 
3). In the diabetic group, 45% had the 
GG genotype, compared with 25% in 
healthy controls. There was a statisti-
cally significant difference between 
these two groups (p-value = 0.014) and 
the odd ratio (OR) for risk of develop-
ing T2D in patients having GG geno-
type was 1.97 (95% CI: 0.80-4.87) as 
shown in (Table 2).
Table 2: Genotype determining risk of UCP2 –866G>A among obesity, T2D and obese-T2D 
Saudi subjects.
Populations n
UCP2 –866G/A genotypes Subjects (%)
p-value* OD (95% CI)A/A (%) G/A (%) G/G (%)
Obese 110 12 (11) 36 (33) 62 (56) 0.0001 3.3(1.37-7.98)
Diabetic 81 12 (15) 33 (40) 37 (45) 0.014 1.97(0.80-4.87)
Obese/diabetic 96 19 (20) 41 (43) 36 (37) 0.067 1.21(0.52-2.80)
Control 100 16 (16.0) 59 (59.0) 25 (25.0) - -
* p-value was considered as significant if it is <0.05. 
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A similar finding was also found in the 
allele frequency, where the OR for risk 
of developing T2D in patients having 
G-allele was 1.6 (95% CI: 0.90- 2.79) 
(Table 3). A similar pattern was seen 
also in the obese group, where the fre-
quency of the GG genotype was 56%, 
in obese group 25% in healthy controls 
(p-value = 0.0001). The OR for risk of 
developing obesity in patients having 
GG genotype was 3.3 (95% CI 1.37-
7.98) (Table 2). A similar finding was 
found in the allele frequency and the 
OR for risk of developing was 2.3 (95% 
CI: 1.28- 4.16) in those patients having 
G-allele (Table 3).
Table 3: UCP2 –866G>A alleles determining risk in obesity, T2D and obese-T2D.
Populations n UCP2 –866G/A Alleles OD (95%, CI)
G-allele A-allele
Obese 110 0.73 0.27 2.3 (1.28-4.16)
Diabetic 81 0.65 0.35 1.6 (0.90-2.79)
Obese/diabetic 96 0.59 0.41 1.2 (0.7-2.15)
Control 100 0.54 0.46
The GG genotype frequency showed 
no statistical significant differences 
between healthy and obese-diabetic 
groups (25% and 37 %, retrospectively; 
p-value = 0.067). The OR for risk of 
developing obesity and T2D in patients 
having GG genotype was 1.21 (95% CI: 
0.52-2.80) (Table 2). A similar finding 
was found in the allele frequency, where 
the OR for risk of developing obesity 
and T2D in patients having G-allele 
was 1.2 (95% CI: 0.7-2.15) (Table 3).
DISCUSSION                                                       
Obesity and T2D are major health 
problems all over the world19. Both 
conditions are considered as a poly-
genic disorder in which environmen-
tal factors interact with genetic varia-
tion in the predisposition to these 
diseases20-22. Identification of candidate 
genes responsible for obesity and T2D 
is an important to understand the mo-
lecular mechanism underlying these 
conditions. The UCP2 which expressed 
in pancreatic β-cells and adipose tis-
sue, has led to the suggestion that such 
molecule may be able to play an impor-
tant role in the etiology of obesity and 
T2D.12,23 
Previous studies have report-
ed that there is an association 
between – 866G/A polymorphism in 
the promoter region of UCP2 with obe-
sity and T2D.11-13, 24-31 This is the first 
study trying to identify the association 
between –866G/A polymorphism in 
UCP2 with obesity and T2D in Saudi 
population. The results of this study 
showed that the frequencies of GG 
genotype were significantly higher in 
obese populations compared to the con-
trol. The risks of developing obesity in 
individuals having GG genotype was 
increased 3-fold than in individuals 
having other genotypes. These results 
are consistent with previous findings in 
which a higher frequency of G allele in 
obese population was founded12,13. Es-
terbauer et al.12 and Krempler et al.13 
have previously reported that the G al-
lele was associated with reduced adi-
pose tissue mRNA expression in vivo, 
reduced transcriptional activity in vitro 
which increased the risk of obesity. 
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However, other studies showed no as-
sociation of this polymorphism with 
obesity.11 The results of this study 
showed that the frequencies of GG gen-
otype were significantly higher in T2D 
populations compared to the control. 
The risks of developing T2D in indi-
viduals having GG genotype was in-
creased 2-fold than individuals having 
other genotypes18,32. A lack of associa-
tion between obesity and T2D accord-
ing to UCP2 polymorphism genotypes 
was observed in this study. Where the 
results of this study showed no statis-
tically significant association between 
G allele and obese-T2D population, al-
though the G allele was most frequent 
in this population. This finding might 
be due to sample size or this polymor-
phism might be modified by differences 
in environmental factors such as calor-
ic intake which make the effect of the 
polymorphism less pronounced than in 
other populations. Moreover, it could be 
due to the presence of other polymor-
phism in the promoter region of UCP2 
or close located gene which might have 
alternated the effect of this polymor-
phism. There has been relatively little 
pharmacogenetic analysis in Arab pop-
ulations. This study was extended to in-
clude the UCP2 polymorphism analysis 
in different ethnic populations that were 
previously reported and its correlation 
with the results of this study. 
The results of this study demonstrat-
ed that the frequency of the G allele 
was much higher in Saudi obese and 
T2D individuals than in the other eth-
nic groups11-13,24-28,30,31. The differences 
in frequency distribution of G allele 
among different ethnic populations in-
dicated the importance of ethnic stud-
ies for this polymorphism. Therefore, it 
is important to determine the associa-
tion of the –866G/A polymorphism in 
the promoter region of UCP2 with the 
T2D, obesity and obesity-T2D in Saudi 
population.
CONCLUSION                                               
G allele in the promoter region of UCP2 
might be associated with increase risk 
of obesity and T2D in Saudi popula-
tion. These data suggest the possibility 
of using UCP2 as a predictive marker to 
identify those people at high risk of de-
veloping obesity and T2D in the future. 
Further studies with larger population 
are required to confirm this finding.
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